IntegenX, Inc. Appoints Debi Frost to Vice President of Operations

PLEASANTON, Calif., May 27 /PRNewswire/ -- IntegenX, Inc. today announced the appointment of Debi Frost as Vice President of Operations. Ms. Frost will be responsible for the company's operational organization and infrastructure, and will report to Stevan Jovanovich, Ph.D., President and Chief Executive Officer of IntegenX.

Prior to joining IntegenX, Ms. Frost earned positions of increasing operational responsibility over the course of 20 years of service at Applied Biosystems, which has since merged with Life Technologies Corporation. With her prior experience at Applied Biosystems as Vice President of global nucleotide operations, and as Vice President of customer services and distribution, Ms. Frost brings to IntegenX a wealth of supply chain, manufacturing, quality assurance, distribution, and customer service experience for life science and biotech laboratory products. She has also consulted extensively to the life science, nanotechnology, healthcare, and viniculture industries, providing her clients operational assessments and advising them on matters related to infrastructure development, scalability, and strategic vision.

"Debi provides us with proven talent and experience in operations," said Dr. Jovanovich. "Her leadership will be crucial as we continue to strengthen our commercial capabilities."

About IntegenX, Inc.

IntegenX, Inc. (IXI), headquartered in Pleasanton, CA, is a venture-backed, privately held company that produces sample processing systems for life sciences, applied sciences, and healthcare diagnostics research markets. The company's products integrate advanced fluidics and analytical capabilities to produce automated sample-to-answer systems for DNA and RNA sequencing, DNA-based forensics and human identity (HID) testing, biodefense, and molecular diagnostics research. The company's first product, the Apollo 100 System, completely automates sample processing for Sanger cycle sequencing and dramatically reduces process requirements for expensive sequencing reagents. For additional information about IXI, visit http://www.integenx.com.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE IntegenX, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED